Treatment of hairy cell leukemia: long-term results in a developing country
| Autor: | Carlos Alarcón-Urdaneta, Guillermo J. Ruiz-Delgado, David Gómez-Almaguer, Luz Tarín-Arzaga, Guillermo J. Ruiz-Argüelles, Jacqueline Calderón-García |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Developing country Antineoplastic Agents Interferon Recurrence medicine Humans Hairy cell leukemia Longitudinal Studies Cladribine Developing Countries Mexico Aged Aged 80 and over Leukemia Hairy Cell business.industry Remission Induction Interferon-alpha Hematology Long term results Middle Aged medicine.disease Survival Analysis Immunology Female business medicine.drug |
| Zdroj: | Hematology (Amsterdam, Netherlands). 17(3) |
| ISSN: | 1607-8454 |
| Popis: | Twenty-nine consecutive patients with hairy cell leukemia (HCL) were treated in two institutions with interferon (IFN, n = 18) or cladribine (n = 11), between July 1987 and May 2011. Median age was 62 (range 29-83) years; there were 21 males and 8 females. Seven of the 18 patients in the IFN group (39%) achieved a complete remission (CR), whereas all the patients in the 2-CDA group entered a CR. Three patients in the 2-CDA group relapsed and needed an additional course of the drug, 2, 3 and 6 years after the initial one. The median overall survival (OS) of the whole group has not been reached, being above 217 months, the 217-month OS being 91%. The survival of patients treated with either IFN or 2-CDA was not statistically different (94% OS at 217 months versus 91% OS at 133 months, respectively). The data that we present here suggest that treatment of HCL with either 2-CDA or IFN is equally effective; treatment costs with IFN are substantially lower than those of the purine analog. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |